Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Ejhaem
|
February 26, 2024
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia
Céline Row, Nicolas Lechevalier, Jean Philippe Vial, et al.
Plos One
|
March 17, 2017
TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma
Audrey Gros, Elodie Laharanne, Marie Vergier, et al.
Blood Advances
|
September 27, 2021
CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome
Inès Vergnolle, Claudia Douat-Beyries, Serge Boulinguez, et al.
Cancer Medicine
|
February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy
Harmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Alban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Cancers
|
July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
Pierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Cancers
|
March 29, 2020
Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study
Sarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood Advances
|
August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
Pierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Blood Cancer Journal
|
May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
Camille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood Cancer Journal
|
August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
François Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Ejhaem
|
February 26, 2024
Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia
Céline Row, Nicolas Lechevalier, Jean Philippe Vial, et al.
Plos One
|
March 17, 2017
TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma
Audrey Gros, Elodie Laharanne, Marie Vergier, et al.
Blood Advances
|
September 27, 2021
CD158k and PD-1 expressions define heterogeneous subtypes of Sezary syndrome
Inès Vergnolle, Claudia Douat-Beyries, Serge Boulinguez, et al.
Cancer Medicine
|
February 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy
Harmony Leroy, Noémie Gadaud, Emilie Bérard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia
Alban Canali, Inès Vergnolle, Sarah Bertoli, et al.
Cancers
|
July 30, 2020
Real-World Outcomes of Patients with Refractory or Relapsed <i>FLT3</i>-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study
Pierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Cancers
|
March 29, 2020
Outcome of Relapsed or Refractory <i>FLT3</i>-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study
Sarah Bertoli, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood Advances
|
August 14, 2020
Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome
Pierre-Yves Dumas, Sarah Bertoli, Emilie Bérard, et al.
Blood Cancer Journal
|
May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study
Camille Gondran, Pierre-Yves Dumas, Emilie Bérard, et al.
Blood Cancer Journal
|
August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia
François Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
Page
of 3